Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced the appointment of H. Martin Seidel, Ph.D., to its Scientific Advisory Board on March 10, 2026.
Dr. Seidel is CEO of IFM Therapeutics and has extensive experience from Novartis, including advancing programs to clinical stages and successful company exits.
Gary D. Glick, Ph.D., Founder and CEO of Odyssey, praised Seidel's expertise in drug discovery and portfolio strategy, noting prior collaborations with Odyssey's leadership team.
Dr. Seidel expressed enthusiasm for Odyssey's scientific capabilities and aims to contribute to target selection and translation as programs advance to the clinic.
Odyssey, founded in 2021, develops internally discovered medicines targeting disease pathology for deep remission in inflammatory diseases.